Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Generic DrugsDiabetesBiologicsBiosimilar

PUBLISHER: Grand View Research | PRODUCT CODE: 1631141

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1631141

Insulin Market Size, Share & Trends Analysis Report By Product (Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilar), By Application, By Type, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Insulin Market Growth & Trends:

The global insulin market size is estimated to reach USD 23.21 billion by 2030, registering to grow at a CAGR of 3.7% from 2025 to 2030 according to a new report by Grand View Research, Inc. It is an oligopolistic space dominated by companies such as Novo Nordisk A/S, Sanofi, and Eli Lilly and Company. The increasing incidence of diabetes and formulation advancements in insulin delivery are the primary factors driving growth. However, the presence of biosimilars and drugs such as GLP-1 RAs for the treatment of type 2 diabetes can slow down market growth to a certain extent.

Diabetes is one of the fastest-growing chronic diseases in the world. Its prevalence has increased steadily over the past few decades. The prevalence of the disease is growing rapidly in low- and middle-income countries; three in four adults live with diabetes in these countries. According to the International Diabetes Federation (IDF) data from 2021, approximately 643 million individuals will have diabetes by 2030 and 783 million by 2045. In addition, the increase in geriatric and obese populations is another factor driving growth. The overweight population is at risk of developing type 2 diabetes mellitus. According to WHO, in 2020, 1.9 billion adults were found to be overweight, accounting for 39% of the population within that age group.

Formulation advancements in insulin delivery systems are being developed, the release of which is likely to propel the market over the forecast period. In December 2019, Tandem Diabetes Care's Control-IQ, an interoperable device, received FDA authorization for marketing in the U.S. It is an automated insulin dosing algorithm that can be used with other interoperable devices.

The top three manufacturing companies, Eli Lilly and Company, Novo Nordisk A/S, and Sanofi, hold a monopoly. These companies hold more than 90% of the market share. Owing to the oligopolistic nature of the market and patent protection, the cost of insulin is high. Hence, the high cost of products could impede industry growth.

The COVID-19 pandemic caused a detrimental impact on the industry. Individuals with chronic illnesses, such as diabetes, have experienced substantial disruptions in emergency and routine medical care. According to an NCBI article, out of ~30 million diabetic patients in America, about 7.5 million are dependent on insulin. Insulin rationing or hoarding has already been a rampant issue, which increased further amid the pandemic due to supply concerns. However, in several countries, the effect of COVID-19 declined to post the third quarter of 2020, which helped the market regain traction.

Insulin Market Report Highlights:

  • The long-acting insulin segment dominated the market and accounted for the largest revenue share of 52.4% in 2024.
  • The type 1 diabetes mellitus segment dominated the market and accounted for the largest revenue share of 78.8% in 2024, driven by the rising incidence of this autoimmune condition among children and adults.
  • The analog insulin segment dominated the market and accounted for the largest revenue share of 87.3% in 2024 due to its advantages over human insulin.
  • The retail pharmacy segment dominated the market and accounted for the largest revenue share of 90.0% in 2024.
Show more
Product Code: GVR-4-68039-951-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Type
    • 1.2.3. Application
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional Scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Insulin Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increase in prevalence of diabetes
      • 3.2.1.2. Increase in geriatric and obese population
      • 3.2.1.3. Formulation advancements in insulin delivery systems
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of insulin
      • 3.2.2.2. Poor reimbursement policies
      • 3.2.2.3. Launch of insulin biosimilars and increasing penetration of glp-1 agonists
  • 3.3. Insulin Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Insulin Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Insulin Market: Product Movement Analysis
  • 4.3. Insulin Market by Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Rapid-Acting Insulin
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Long-Acting Insulin
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Combination Insulin
    • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Biosimilar
    • 4.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Insulin Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Insulin Market: Type Movement Analysis
  • 5.3. Insulin Market by Type Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Human Insulin
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Insulin Analog
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Insulin Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Insulin Market: Application Movement Analysis
  • 6.3. Insulin Market by Application Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Type 1 Diabetes Mellitus
    • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Type 2 Diabetes Mellitus
    • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Insulin Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Insulin Market: Distribution Channel Movement Analysis
  • 7.3. Insulin Market by Distribution Channel Outlook (USD Million)
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Hospitals
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Retail Pharmacies
    • 7.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Insulin Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Recent Developments & Impact Analysis by Key Market Participants
  • 9.3. Company Market Share Analysis, 2024
  • 9.4. Key Company Profiles
    • 9.4.1. Novo Nordisk A/S
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Eli Lilly and Company
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Sanofi
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Biocon Ltd
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Wockhardt
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Boehringer Ingelheim International GmbH
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Julphar
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. United Laboratories International Holdings Limited
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Tonghua Dongbao Pharmaceutical Co. Ltd.
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
Show more
Product Code: GVR-4-68039-951-3

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. List of secondary sources
  • Table 4. List of Abbreviations
  • Table 5. North America insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 6. North America insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 7. North America insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 8. North America insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9. U.S. insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 10. U.S. insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 11. U.S. insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 12. U.S. insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13. Canada insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 14. Canada insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 15. Canada insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 16. Canada insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Europe insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 18. Europe insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 19. Europe insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 20. Europe insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21. UK insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 22. UK insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 23. UK insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 24. UK insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25. Germany insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 26. Germany insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 27. Germany insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 28. Germany insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29. France insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 30. France insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 31. France insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 32. France insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Italy insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 34. Italy insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 35. Italy insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 36. Italy insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37. Spain insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 38. Spain insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 39. Spain insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 40. Spain insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41. Asia Pacific insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 42. Asia Pacific insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 43. Asia Pacific insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 44. Asia Pacific insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Japan insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 46. Japan insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 47. Japan insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 48. Japan insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49. China insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 50. China insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 51. China insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 52. China insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53. India insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 54. India insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 55. India insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 56. India insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57. Australia insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 58. Australia insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 59. Australia insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 60. Australia insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. South Korea insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 62. South Korea insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 63. South Korea insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 64. South Korea insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65. Latin America insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 66. Latin America insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 67. Latin America insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 68. Latin America insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69. Brazil insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 70. Brazil insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 71. Brazil insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 72. Brazil insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 73. Mexico insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 74. Mexico insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 75. Mexico insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 76. Mexico insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77. Argentina insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 78. Argentina insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 79. Argentina insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 80. Argentina insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81. MEA insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 82. MEA insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 83. MEA insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 84. MEA insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85. South Africa insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 86. South Africa insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 87. South Africa insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 88. South Africa insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 90. Saudi Arabia insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 91. Saudi Arabia insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 92. Saudi Arabia insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93. UAE insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 94. UAE insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 95. UAE insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 96. UAE insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD) Million
  • Table 97. List of key distributors

List of Figures

  • Fig. 1 Market research approaches
  • Fig. 2 Value chain-based sizing & forecasting
  • Fig. 3 Market formulation & validation
  • Fig. 4 Insulin market segmentation
  • Fig. 5 Market driver analysis (current & future impact)
  • Fig. 6 Market restraint analysis (current & future impact)
  • Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 8 Porter's five forces analysis
  • Fig. 9 Global insulin market: Product type outlook and key takeaways
  • Fig. 10 Global insulin market: Product type movement analysis
  • Fig. 11 Rapid-acting insulin market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 12 Long-acting insulin market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 13 Combination Insulin market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 14 Biosimilar market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Others market estimates and forecast, estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Global insulin market: type outlook and key takeaways
  • Fig. 17 Global insulin market: Type movement analysis
  • Fig. 18 Human insulin market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 19 Insulin Analog market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 20 Global Insulin market: Application type outlook and key takeaways
  • Fig. 21 Global insulin market: Application type movement analysis
  • Fig. 22 Type 1 diabetes mellitus market estimates and forecast, 2018-2030
  • Fig. 23 Type 2 diabetes mellitus market estimates and forecast, 2018-2030
  • Fig. 24 Global insulin market: Distribution channel outlook and key takeaways
  • Fig. 25 Global insulin market: Distribution channel movement analysis
  • Fig. 26 Hospital pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 27 Retail pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 North America Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 US Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Canada Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 UK Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Germany Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 France Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Italy Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Spain Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Norway Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Japan Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 China Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 India Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Australia Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 South Korea Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 MEA Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 UAE Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 List of key emerging company's/disruptors/innovators
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!